Medicine and Dentistry
Adjuvant Therapy
12%
Bevacizumab
13%
Biological Marker
9%
Body Mass Index
14%
Cancer
19%
Cancer Cell
11%
Carboplatin
8%
Carcinosarcoma
13%
Cell Line
10%
Cervical Cancer
30%
Chemoradiotherapy
10%
Cisplatin
8%
Clinical Trial
9%
Diseases
39%
Doxorubicin
9%
Endometrium Carcinoma
10%
Fallopian Tube
20%
Female Genital Tract Cancer
16%
Gynecological Oncology
68%
Hazard Ratio
14%
Homologous Recombination
8%
Hydrocortisone
14%
Immunohistochemistry
8%
Intensity Modulated Radiation Therapy
10%
Interleukin 6
8%
Kaplan Meier Method
9%
Krukenberg Tumor
50%
Malignant Neoplasm
37%
Metastatic Carcinoma
20%
Multivariate Analysis
11%
Neoplasm
68%
Oncologist
12%
Oncology
31%
Ovarian Cancer
100%
Overall Survival
45%
Paclitaxel
24%
Pelvis
11%
Positron Emission Tomography
9%
Primary Peritoneal Cancer
8%
Progression Free Survival
20%
Proportional Hazards Model
9%
Quality of Life
13%
Radiation Therapy
15%
Recurrent Disease
33%
Recurrent Ovarian Cancer
9%
Tumor Cell
10%
Tumor Microenvironment
9%
Tumor Progression
10%
Uterine Cancer
91%
Wound Complication
11%
Keyphrases
Adjuvant Therapy
14%
Advanced Ovarian Cancer
14%
AEE788
9%
Bevacizumab
17%
Body Mass Index
11%
Cancer Patients
18%
Cervical Cancer
18%
Cervical Cancer Patients
10%
Chemotherapy
32%
Cisplatin
10%
Confidence Interval
21%
Cortisol
10%
Endometrial Cancer
63%
Endometrioid Endometrial Cancer
14%
Epithelial Ovarian Cancer
25%
Fallopian Tube
22%
Group Studies
27%
Gynecologic Oncologist
12%
Gynecologic Oncology
37%
Gynecologic Oncology Group
31%
Gynecological Cancer
16%
Hazard Ratio
12%
High Risk
9%
High-grade Serous Ovarian Cancer (HGSOC)
9%
Intensity-modulated Radiation Therapy
9%
Interleukin-6
10%
Multivariate Analysis
10%
NRG Oncology
29%
Obesity
9%
Oncology Patients
25%
Ovarian Cancer
74%
Ovarian Cancer Cells
11%
Ovarian Cancer Patients
30%
Ovarian Carcinoma
18%
Overall Survival
44%
Paclitaxel
25%
Phase II Trial
9%
Primary Peritoneal Cancer
17%
Progression-free Survival
15%
Quality of Life
16%
Recurrent Endometrial Cancer
10%
Risk Factors
10%
Survival Outcomes
10%
Tumor
30%
Tumor Cells
11%
Tumor Growth
12%
Tumor Microenvironment
12%
Uterine Carcinosarcoma
9%
Vascular Endothelial Growth Factor
9%
Wound Complications
11%